Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post about recent paper by Richard S Finn et al. on X:
“Adding Tiragolumab to Atezo-Beva in 1L of HCC MORPHEUS-Liver:
- Anti-TIGIT, phase 1b–2
- ORR: 43% vs. 11%
- Serious adverse events: 53% vs. 56%
- mPFS: 12.3 vs. 4.2 mo
- mOS: 28.9 vs. 15.1 mo”
Authors: Prof Richard S Finn, Prof Baek-Yeol Ryoo, Prof Chih-Hung Hsu, Daneng Li, Prof Adam M Burgoyne, Christopher Cotter, Shreya Badhrinarayanan, Yulei Wang, Anqi Yin, Tirupathi Rao Edubilli, Sami Mahrus, Matthew H Secrest, Colby S Shemesh, Nancy Yu, Stephen P Hack, Edward Cha, Prof Ed Gane
